Clinical Trial Update: Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib with pegylated liposomal doxorubicin in previously untreated symptomatic multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Pegylated liposomal doxorubicin hydrochloride (pegylated liposomal doxorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Status: COMPLETED